Anixa Biosciences, Inc. (ANIX): Price and Financial Metrics
ANIX Price/Volume Stats
Current price | $3.33 | 52-week high | $6.45 |
Prev. close | $3.23 | 52-week low | $2.75 |
Day low | $3.21 | Volume | 21,635 |
Day high | $3.39 | Avg. volume | 154,618 |
50-day MA | $3.93 | Dividend yield | N/A |
200-day MA | $3.59 | Market Cap | 106.23M |
ANIX Stock Price Chart Interactive Chart >
ANIX POWR Grades
- Sentiment is the dimension where ANIX ranks best; there it ranks ahead of 95.19% of US stocks.
- The strongest trend for ANIX is in Growth, which has been heading up over the past 26 weeks.
- ANIX's current lowest rank is in the Quality metric (where it is better than 6.56% of US stocks).
ANIX Stock Summary
- For ANIX, its debt to operating expenses ratio is greater than that reported by just 5.76% of US equities we're observing.
- ANIX's price/sales ratio is 588.85; that's higher than the P/S ratio of 99.08% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.03 for ANIXA BIOSCIENCES INC; that's greater than it is for only 7.25% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to ANIXA BIOSCIENCES INC are AI, LIDR, TXG, OLO, and KIND.
- ANIX's SEC filings can be seen here. And to visit ANIXA BIOSCIENCES INC's official web site, go to www.anixa.com.
ANIX Valuation Summary
- ANIX's price/sales ratio is 574.3; this is 26004.55% higher than that of the median Healthcare stock.
- ANIX's price/sales ratio has moved up 389.5 over the prior 243 months.
Below are key valuation metrics over time for ANIX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ANIX | 2023-12-29 | 574.3 | 4.7 | -11.4 | -11.1 |
ANIX | 2023-12-28 | 575.7 | 4.7 | -11.4 | -11.1 |
ANIX | 2023-12-27 | 582.9 | 4.8 | -11.6 | -11.3 |
ANIX | 2023-12-26 | 571.0 | 4.7 | -11.3 | -11.0 |
ANIX | 2023-12-22 | 577.1 | 4.7 | -11.4 | -11.2 |
ANIX | 2023-12-21 | 561.0 | 4.6 | -11.1 | -10.8 |
ANIX Growth Metrics
- Its 3 year net income to common stockholders growth rate is now at 13.62%.
- Its 4 year price growth rate is now at 129.47%.
- Its 4 year net income to common stockholders growth rate is now at -69.26%.
The table below shows ANIX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 0 | -6.492 | -13.595 |
2022-06-30 | 0 | -5.943174 | -14.13227 |
2022-03-31 | 0 | -6.027935 | -15.72026 |
2021-12-31 | 0 | -4.963423 | -14.57511 |
2021-09-30 | 0.5125 | -4.936881 | -12.9544 |
2021-06-30 | 0.5125 | -5.306789 | -11.16517 |
ANIX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ANIX has a Quality Grade of F, ranking ahead of 4.41% of graded US stocks.
- ANIX's asset turnover comes in at 0.021 -- ranking 366th of 682 Pharmaceutical Products stocks.
- ALIM, BDSI, and ACOR are the stocks whose asset turnover ratios are most correlated with ANIX.
The table below shows ANIX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-07-31 | 0.021 | 0.249 | -2.121 |
2021-04-30 | 0.029 | 0.249 | -2.555 |
2021-01-31 | 0.052 | 0.249 | -5.229 |
2020-10-31 | 0.000 | NA | -4.690 |
2020-07-31 | 0.000 | NA | -4.964 |
2020-04-30 | 0.000 | NA | -5.669 |
ANIX Price Target
For more insight on analysts targets of ANIX, see our ANIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $9.75 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Anixa Biosciences, Inc. (ANIX) Company Bio
Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine against triple negative breast cancer; and chimeric endocrine receptor T-cell technology focused on treating ovarian cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.
Latest ANIX News From Around the Web
Below are the latest news stories about ANIXA BIOSCIENCES INC that investors may wish to consider to help them evaluate ANIX as an investment opportunity.
Anixa Biosciences to Present at Biotech Showcase 2024Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California in parallel to the 42nd Annual J.P. Morgan Healthcare Conference ("JPM Week 2024"). |
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023Some of the most explosive opportunities can be found in biotech stocks. |
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer VaccineAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced new and updated positive results from the Phase 1 clinical trial of its breast cancer vaccine. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense. |
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer VaccineAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, will publicly release new data this evening from the ongoing Phase 1 clinical trial of its breast cancer vaccine, which was presented for the first time today at the 2023 San Antonio Breast Cancer Symposium ("SABCS"). All interested parties are invited to join an upcoming conference call today at 6:30 pm ET to discuss the data. |
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine TechnologyAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has received an "Intention to Grant" notice from the European Patent Office ("EPO") for the patent application titled "Ovarian Cancer Vaccines." |
ANIX Price Returns
1-mo | -6.20% |
3-mo | -14.18% |
6-mo | 1.83% |
1-year | -28.39% |
3-year | -31.62% |
5-year | -26.33% |
YTD | -14.18% |
2023 | -8.71% |
2022 | 43.10% |
2021 | -3.26% |
2020 | -6.40% |
2019 | -16.75% |
Continue Researching ANIX
Here are a few links from around the web to help you further your research on Anixa Biosciences Inc's stock as an investment opportunity:Anixa Biosciences Inc (ANIX) Stock Price | Nasdaq
Anixa Biosciences Inc (ANIX) Stock Quote, History and News - Yahoo Finance
Anixa Biosciences Inc (ANIX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...